Early recognition and treatment initiation are pivotal in managing Alzheimer k disease (AD). Once a diagnosis of AD is made, a treatment plan is developed and should include treatment initiation with cholinesterase inhibitors (ChEfs) to improve cognition, management of comorbid conditions, and treat behavioral symptoms. Caregiver compliance is integral to AD treatment success. The purpose of this report is to present two real case studies of “suspected” AD or related dementia and stress the significance of early and accurate diagnosis in disease management. In case 1, a caregiver reports gradual but progressive loss of memory, and the patient himself complains of memory impairment. Neuroimaging analysis confirms “typical” AD. In case 2, initiation of ChEI therapy is followed by substantial clinical improvement in the face of a complex medical picture, and neuroimaging revealing more neurodegenerative changes than could be accountedfor by “pure” AD.
1. Ernst RL, Hay JW: The US economic and social costs of Alzheimer's disease revisited. Am JPublic Health. 1994; 84: 1261-1264.
2.
2. Stommel M, Collins CE, Given BA: The costs of family contributions to the care of persons with dementia. Gerontologist. 1994; 34(2): 199-205.
3.
3. Huang L, Cartwright W, Hu T: The economic cost of senile dementia in the United States, 1985. Public Health Rep. 1988; 103: 3-7.
4.
4. Evans DA: Estimated prevalence of Alzheimer's disease in the United States. Milbank Q. 1990; 68: 267-289.
5.
5. Small GW, McDonnell DD, Brooks RL, et al.: The impact of symptom severity on the cost of Alzheimer's disease. JAm Geriatr Soc. 2002; 50: 321-327.
6.
6. Leon J, Cheng CK, Neumann PJ: Alzheimer's disease care: Costs and potential savings. Health Aff(Millwood). 1998; 17(6): 206-216.
7.
7. Hebert LE, Scherr PA, Bienias JL, et al.: Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Arch Neurol. 2003; 60(8): 1119-1122.
8.
8. Sloane PD, Zimmerman S, Suchindran C, et al.: The public health impact of Alzheimer's disease, 2000-2050: Potential implication of treatment advances. Annu Rev Public Health. 2002; 23: 213-231.
9.
9. Tuokko H, Garrett DD, McDowell I, et al.: Cognitive decline in high-functioning older adults: Reserve or ascertainment bias?Aging Ment Health. 2003; 7(4): 259-270.
10.
10. Rogers SL, Doody RS, Mohs RC, et al.: Donepezil improves cognition and global function in Alzheimer disease: A 15-week, doubleblind, placebo-controlled study. Arch Intern Med. 1998; 158(9): 1021-1031.
11.
11. Rogers SL, Farlow MR, Doody RS, et al.: A 24-week, doubleblind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 1998; 50(1): 136-145.
12.
12. Burns A, Rossor M, Hecker J, et al.: The effects of donepezil in Alzheimer's disease-results from a multinational trial. Dement Geriatr Cogn Disord. 1999; 10(3): 237-244.
13.
13. Corey-Bloom J, Anand R, Veach J, for the ENA 713 B352 Study Group: A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol. 1998; 1: 55-65.
14.
14. Rosler M, Anand R, Cicin-Sain A, et al.: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. BMJ. 1999; 318(7184): 633-638.
15.
15. Tariot PN, Solomon PR, Morris JC, et al.: A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology. 2000; 54(12): 2269-2276.
16.
16. Wilcock GK, Lilienfeld S, Gaens E, on behalf of the Galantamine International-I Study Group: Effficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial. BMJ2000; 321(7274): 1445-1449.
17.
17. Hill JW, Futterman R, Mastey V, et al.: The effect of donepezil therapy on health costs in a Medicare managed care plan. Manag Care Interface. 2002; 15(3): 63-70.
18.
18. Farlow M, Anand R, Messina J Jr, et al.: A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol. 2000; 44(4): 236-241.
19.
19. Doody RS, Geldmacher DS, Gordon B, et al.: Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients withAlzheimer disease. Arch Neurol. 2001; 58: 427-433.
20.
20. Raskind MA, Peskind ER, Wessel T, et al.: Galantamine in AD: A six-month randomized, placebo-controlled trial with a six-month extension. Neurology. 2000; 54(12): 2261-2268.
21.
21. Winblad B, Engedal K, Soininen H, et al.: A 1 -year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001; 57(3): 489-495.
22.
22. Geldmacher DS, Provenzano G, McRae T, et al.: Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. JAm Geriatr Soc. 2003; 51(7): 937-944.
23.
23. Lopez OL, Becker JT, Wisniewski S, et al.: Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J NeurolNeurosurg Psychiatry. 2002; 72(3): 310-314.
24.
24. Knopman D, Schneider L, Davis K, et al.: Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality. Tacrine Study Group. Neurology. 1996; 47(1): 166-177.
25.
25. Courtney C, Farrell D, Gray R, et al.: Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomised double-blind trial. Lancet. 2004; 363(9427): 2105-2115.
26.
26. Small GW, Rabins PV, Barry PP, et al.: Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA. 1997; 278(16): 1363-1371.
27.
27. Morris JC, Storandt M, Miller JP, et al.: Mild cognitive impairment represents early-stage Alzheimer's disease. Arch Neurol. 2001; 58: 397-405.
28.
28. Galasko DR, Gould RL, Abramson IS, et al.: Measuring cognitive change in a cohort of patients with Alzheimer's disease. Stat Med. 2000; 19(11-12): 1421-1432.
29.
29. Boise L, Camicioli R, Morgan DL, et al.: Diagnosing dementia: Perspectives of primary care physicians. Gerontologist. 1999; 39(4): 457-464.
30.
30. Geldmacher DS: Cost-effective recognition and diagnosis of dementia. SeminNeurol. 2002; 22(1): 63-70.
31.
31. Knopman DS, DeKosky ST, Cummings JL, et al.: Practice parameter: diagnosis of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001; 56GB files: 1143-1153.
32.
32. Small GW, Mazziotta JC, Collins MT, et al.: Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at riskfor familial Alzheimer disease. JAMA. 1995; 273(12): 942-947.
33.
33. Small GW, Ercoli LM, Silverman DH, et al.: Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc NatlAcad Sci USA. 2000; 97(11): 6037-6042.
34.
34. Silverman DH, Small GW, Chang CY, et al.: Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA. 2001; 286(17): 2120-2127.
35.
35. Reiman E, Caselli R, Yun L, et al.: Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoproteinE. NEngl JMed. 1996; 334(12): 752-758.
36.
36. Minoshima S, Giordani B, Berent S, et al.: Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997; 42(1): 85-94.
37.
37. Silverman DHS, Cummings J, Small GW, et al.: Added clinical benefit of incorporating 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography into the clinical evaluation of patients with cognitive impairment. Mol Imaging Biol. 2002; 4(4): 283-293.
38.
38. Silverman DH, Gambhir SS, Huang HW, et al.: Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: A comparison of predicted costs and benefits. JNucl Med. 2002; 43(2): 253-266.
39.
39. Newberg AB, Alavi A: The role of PET imaging in the management of patients with central nervous system disorders. Radiol Clin North Am. 2005; 43(1): 49-65.
40.
40. Silverman DH: Brain 1 8F-FDG PET in the diagnosis of neurodegenerative dementias: Comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med. 2004; 45(4): 594-607.
41.
41. Seltzer B, Zolnouni P, Nunez M, et al.: Donepezil treatment benefits in early-stage Alzheimer's disease. JAm Geriatr Soc. 2003; 51(4): S100-S101.
42.
42. Rogers SL, Friedhoff LT, for the Donepezil Study Group: The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia. 1996; 7(6): 293-303.
43.
43. Rogers SL, Doody RS, Pratt RD, et al.: Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: Final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol. 2000; 10: 195-203.
44.
44. Feldman H, Gauthier S, Hecker J, et al.: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001; 57(4): 613-620.
46. Winblad B, Engedal K, Soininen H, et al.: Long-term efficacy of donepezil in patients with mild to moderate Alzheimer's disease: Results from a one-year placebo-controlled study and two-year follow-up study [abstract]. IntPsychogeriatr. 2003; 15(suppl 2): 293-294.
47.
47. Swanberg M, Cummings J: Benefit-risk considerations in the treatment of dementia with lewy bodies. Drug Safety. 2002;25(7): 511-523.
